Sunitinib demonstrated encouraging activity in patients with recurrent and progressive meningioma, according to results of a prospective, multicenter, single-arm phase 2 study.
The analysis included 36 patients with atypical (n=30) or anaplastic (n=6) meningioma.
Those enrolled in the primary cohort had surgery- and radiation-refractory grade II to grade III disease, a group for whom no proven effective therapy exists. The 13 patients enrolled in an exploratory cohort had grade I meningioma, hemangiopericytoma or hemangioblastoma.
All patients were heavily pretreated and had experienced a median of five disease recurrences (range, 2-10).
All patients received 50 mg daily sunitinib (Sutent, Pfizer) for 28 days.
Six-month PFS served as the primary outcome measure. Radiographic response rate, safety, PFS and OS served as secondary outcome measures.
The study — conducted by Thomas J. Kaley, MD, of the department of neurology at Memorial Sloan Kettering Cancer Center, and colleagues — met its primary endpoint, yielding a 6-month PFS rate of 42%.
Median PFS was 5.2 months (95% CI, 0.8-8.3) and median OS was 24.6 months (95% CI, 16.5-38.4).
Kaley and colleagues reported longer median PFS among patients with VEGFR-2–positive patients than VEGFR-2–negative patients (6.4 months vs. 1.4 months; P=.005).
Adverse events included one grade 5 intratumoral hemorrhage, two grade 3 CNS/intratumoral hemorrhages, one grade 4 CNS/intratumoral hemorrhage, one grade 3 thrombotic microangiopathy, one grade 4 thrombotic microangiopathy, and one grade 3 gastrointestinal perforation.
Disclosure: See the study for a full list of the researchers’ relevant financial disclosures.